
Non-SCID T-Cell Lymphopenia Screening: System-Wide Cost Analysis
Newborn screening for non-SCID T-cell lymphopenia flags a significant number of infants, but the long-term clinical impact remains unclear, leading to potential over-testing and resource strain. A Swiss cohort study highlights the complexities of managing these cases, prompting a need for careful cost-benefit analysis of current screening protocols.







